Gahlot, RKumar, SGarg, SChawla, SKalra, BS.2023-08-192023-08-192023-03Gahlot R, Kumar S, Garg S, Chawla S, Kalra BS.. Efficacy and safety of Saroglitazar and Fenofibrate in the treatment of diabetic dyslipidaemia: A pilot study. Indian Journal of Physiology and Pharmacology. 2023 Mar; 67(1): 15-200019-54992582-2799http://imsear.searo.who.int/handle/123456789/223972Objectives: Diabetic dyslipidaemia (DD) is characterised by hypertriglyceridaemia and elevated or normal levels of low-density lipoprotein cholesterol and decreased levels of high-density lipoprotein cholesterol with Type 2 diabetes mellitus. Statins and anti-diabetic medication are coprescribed for optimal control. Materials and Methods: The objective of the study was to compare the safety and efficacy of Saroglitazar 4-mg and Fenofibrate 200 mg in combination with low dose Atorvastatin (10 mg) in patients with DD. Run-in period of 4 weeks for life-style and diet modification followed by 12 weeks of treatment with saroglitazar or fenofibrate and low dose of atorvastatin was followed. Primary outcome of this study was an absolute change in serum triglyceride level at baseline and end of treatment period (12 weeks). Secondary outcome was changed from baseline lipid profile, fasting blood glucose and glycosylated haemoglobin (HbA1c) at the end of treatment period. Safety assessment was also done during the duration of study. Results: Forty patients of DD were randomly divided into two groups. One group received Saroglitazar 4 mg along with Atorvastatin 10 mg. Patients in second group received Fenofibrate 200 mg along with Atorvastatin 10 mg. Improvement in deranged lipid levels in both the groups was observed and this difference in improvement statistically was not found to be significant. We also observed that Saroglitazar significantly improves glycaemic profile by decreasing fasting blood sugar levels and HbA1c (P = 0.01, P < 0.01). Adverse events reported during this study were mild and none of the patients reported serious adverse events. Conclusion: Saroglitazar could be a potential drug to control both hyperglycaemia and dyslipidaemia in patients with DD.Diabetic dyslipidaemiaDyslipidemiaFenofibrateHyperlipidaemiaPeroxisome proliferatoractivated receptorSaroglitazarTriglyceridesJournal ArticleIndiaDepartment of Pharmacology, Maulana Azad Medical College, Delhi, IndiaDepartment of Pharmacology, ESIC Dental College, Delhi, IndiaDepartment of Medicine, Lok Nayak Hospital, Delhi, India